Abstract
Background Curcumin, which is derived from turmeric root and is widely utilized in Asian cuisines, exhibits notable anti-inflammatory effects. Its consumption has proven beneficial in alleviating inflammation-related disorders such as ulcerative colitis, rheumatoid arthritis, and esophagitis. These anti-inflammatory properties might also provide advantages in reducing cardiovascular complications, such as atherosclerosis, which is particularly prevalent among diabetic individuals. This study aimed to evaluate the efficacy of curcumin in decreasing the risk of atherogenesis in obese patients with type 2 diabetes.
Methods The study employed a rigorous randomized, double-blind, placebo-controlled trial design with 265 participants who were diagnosed with type 2 diabetes. Subjects were randomly assigned to receive either curcumin capsules or a placebo over 12 months. The key metrics used to assess atherogenic risk reduction included pulse wave velocity and various metabolic profiles. These profiles included low-density lipoprotein cholesterol, small dense low-density lipoprotein cholesterol, apolipoprotein B, triglyceride to high-density lipoprotein ratio, uric acid, waist circumference, total body fat, and visceral fat. Measurements were recorded at baseline and at 3-, 6-, 9-, and 12-month intervals throughout the treatment phase.
Results After 12 months, participants receiving curcumin exhibited a significant reduction in pulse wave velocity (P < 0.001). Furthermore, this group also showed significantly reduced levels of various cardiometabolic risk biomarkers. These included low-density lipoprotein cholesterol, small dense low-density lipoprotein cholesterol, apolipoprotein B, the triglyceride to high-density lipoprotein ratio, uric acid, waist circumference, and total body fat, all with P values less than 0.001. Additionally, visceral fat levels were reduced, with a P value of 0.01. Markers of inflammation (high-sensitivity C-reactive protein, interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha) were also significantly lower in the curcumin group than in the placebo group, with P values less than 0.001.
Conclusions The 12-month administration of curcumin to patients with type 2 diabetes and obesity significantly reduced pulse wave velocity and improved cardiometabolic risk profiles. It also demonstrated substantial anti-inflammatory effects with minimal adverse outcomes. These findings suggest that curcumin treatment may effectively reduce atherogenic risks in obese patients with type 2 diabetes.
Trial registration Thai Clinical Trials Registry: TCTR20140303003
What Is New?
Individual patient data from randomized trials of curcumin extract versus placebo, spanning a 12-month period and including a rather large sample size (n=227), are analyzed collectively.
Curcumin extract use resulted in a significant reduction in pulse wave velocity and showed a significant improvement in cardiometabolic risk profiles.
What Are the Clinical Implications?
The efficacy and safety data from randomized clinical trials supports the use of curcumin extract over placebo for mitigating inflammation and improving cardiometabolic risk factors.
Curcumin supplementation shows promise in protecting against atherosclerosis and related cardiovascular diseases in patients with T2DM and obesity.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Trial registration: Thai Clinical Trials Registry: TCTR20140303003
Funding Statement
This research was financially supported by the joint funding between the Thailand Research Fund and the Department for Development of Thai Traditional and Alternative Medicine, Ministry of Public Health (to S.C.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Ethics Committee of Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
Researchers who want access to our data must submit a proposal containing a valuable research question. A committee made up of members from the trial management group, including senior figures in statistics and clinical fields, will evaluate these proposals. Data sharing will adhere to the HRH Princess Maha Chakri Sirindhorn Medical Center's data sharing policy.
